Ubs Asset Management Americas Inc Immunovant, Inc. Transaction History

Ubs Asset Management Americas Inc

$477 Billion
Q2 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 200,260 shares of IMVT stock, worth $5.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

200,260

Previous 140,091 42.95%

Holding current value

$5.51 Million

Previous $3.85 Million 42.98%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	N/A	60,169 Added 42.95%	200,260 $5.51 Million
Q1 2025 May 19, 2025	SELL	N/A	-139,161 Reduced 49.83%	140,091 $3.85 Million
Q4 2024 Feb 14, 2025	SELL	N/A	-31,578 Reduced 10.16%	279,252 $7.68 Million
Q3 2024 Nov 14, 2024	SELL	$27.51 - $27.51 $266,241 - $266,241	-9,678 Reduced 3.02%	310,830 $8.55 Million
Q2 2024 Aug 13, 2024	BUY	$25.1 - $31.61 $2.87 Million - $3.62 Million	114,477 Added 55.56%	320,508 $8.46 Million
Q1 2024 May 15, 2024	SELL	$30.27 - $43.79 $46,040 - $66,604	-1,521 Reduced 0.73%	206,031 $6.66 Million
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $3.9 Million - $5.51 Million	124,636 Added 150.32%	207,552 $8.74 Million
Q3 2023 Nov 13, 2023	BUY	$18.55 - $39.96 $578,648 - $1.25 Million	31,194 Added 60.31%	82,916 $3.18 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $121,671 - $157,128	7,968 Added 18.21%	51,722 $802,000
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $42,235 - $113,759	6,409 Added 17.16%	43,754 $776,000
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $57,366 - $92,982	-14,597 Reduced 28.1%	37,345 $208,000
Q3 2021 Nov 15, 2021	SELL	$7.01 - $11.37 $57,867 - $93,859	-8,255 Reduced 13.71%	51,942 $451,000
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $156,510 - $280,552	16,650 Added 38.23%	60,197 $636,000
Q1 2021 May 14, 2021	SELL	$13.08 - $49.6 $14,309 - $54,262	-1,094 Reduced 2.45%	43,547 $698,000
Q4 2020 Mar 01, 2021	BUY	$36.36 - $52.71 $895,946 - $1.3 Million	24,641 Added 123.21%	44,641 $2.06 Million
Q3 2020 Nov 13, 2020	BUY	$22.61 - $38.9 $250,971 - $431,790	11,100 Added 124.72%	20,000 $703,000
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $123,443 - $253,116	8,900 New	8,900 $216,000

Others Institutions Holding IMVT

# of Institutions

192

Shares Held

78.7M

Call Options Held

401K

Put Options Held

354K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Immunovant, Inc. Transaction History